Biological Features and Clinical Outcome in Infant Neuroblastoma: a Multicenter Experience in Beijing
Zhang Shihan,Zhang Weiling,Jin Mei,Sun Qing,Zhang Zhaoxia,Qin Hong,Su Yan,Zhi Tian,Xie Yao,Gao Yang Xu,Zhang Xiaolun,Li Long,Liu Rong,Zhao Weihong,Wang Huanmin,Huang Dongsheng,Ma Xiaoli
DOI: https://doi.org/10.1007/s00431-021-03989-1
2021-01-01
European Journal of Pediatrics
Abstract:Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, with 37% of patients diagnosed during infancy. This study is aimed at evaluating the survival outcome in infants diagnosed with neuroblastoma. This was a retrospective cohort study including patients under the age of 12 months with neuroblastoma from four tertiary referral centers in Beijing, China (Beijing Children’s Hospital, Beijing Tongren Hospital, Peking University First Hospital, and Capital Institute of Pediatrics). Two hundred and forty-seven infants with neuroblastoma were included (male = 132 and female = 115). 91.1% ( n = 225) patients were classified as having low-risk or intermediate-risk disease and 8.9% ( n = 22) as having high-risk disease. The most common metastatic site is distant lymph node ( n =89, 36.0%), followed by liver ( n =57, 23.1%), bone ( n =42, 17.0%), bone marrow ( n =37, 15.0%), soft tissue ( n =25, 10%), and central nervous system ( n =4, 1.6%). MYCN amplification was present in 9.9% of tumor samples, chromosome 1p or 11q aberration in 14%. Treatment involved surgery alone in 9.7% of patients ( n =24, all with low-risk disease), surgery followed by adjuvant chemotherapy in 50.2% ( n =124), neoadjuvant chemotherapy followed by surgery in 40.1% ( n =97), and chemotherapy alone in 0.8% ( n =2). 4.9% ( n =12) patients died, and the major cause of death is disease progression. Three-year event-free and overall survival were 91.6%±2.1% and 97.4%±1.1%, respectively, in patients with low- or intermediate-risk disease, and 58.7%±11.5% and 63.6%±11.2%, respectively, in those with high-risk disease. Conclusions : Infants with neuroblastoma achieve a reasonable clinical outcome when treated with surgery with or without chemotherapy using a risk-stratified approach in China. Such information will facilitate counseling, therapeutic decision-making, and development of adapted standard-of-care guidelines for future patients in the country. What is Known: • NB is a disease of infancy; 37% of patients are diagnosed as infants. • Most children younger than 12 months of age have a good prognosis even in the presence of metastatic disease. What is New: • Infants with neuroblastoma achieve reasonable clinical outcome when treated with surgery with or without chemotherapy using a risk-stratified approach in China. • CNS metastasis in infants with neuroblastoma is very rare at diagnosis and had a worse prognosis than those without metastasis.